Search:

Login | Subscribe

Home > Companies > Silence Therapeutics

Price	Market	Sector	Market Cap
17.75p (0.00p) 0.00%	AIM	Medicine and Biotech Research	£21.28m

Add to company folder | Print

Related Companies

PLE	16.50p	0.00%
PRM	20.50p	0.00%
PRX	145.00p	0.00%
RNSM	7.75p	0.00%
RCG	34.50p	-1.43%
RGT	6.50p	0.00%
SNG	18.00p	0.00%
TED	11.25p	0.00%
VOX	p
YRK	16.00p	0.00%

Commentary

Drug developer

Recent Articles

Silence mute on rumours

10/08/2007

Recent Announcements

Second Price Monitoring Extn	10/11/2008
Price Monitoring Extension	10/11/2008
Presentations at upcoming con	09/06/2008
Presentation at Conference	06/05/2008
Holding(s) in Company	07/04/2008
Development Concept Supported	07/04/2008
Presentation at Conference	19/11/2007
Conference Attendance	02/11/2007
Conference Attendance	15/06/2007
SR Pharma Name Change	04/05/2007

Articles from the Sector

Stroke hope at ReNeuron	28/11/2008
Futura Medical	28/11/2008
Option deal boosts ImmuPharma	25/11/2008
Digital imager targets AIM	24/11/2008
Vectura loses interim £11.7m	24/11/2008
GW trims loss	19/11/2008
Asterand	18/11/2008
EU trial cheers Plethora	07/11/2008
IS Pharma	05/11/2008
Animalcare nurturing high-margin growth	03/11/2008
More

Financial History

Financial Year End	31/12/2003	31/12/2004	31/12/2005	31/12/2006	31/12/2007
Currency	GBP	GBP	GBP	GBP	GBP
Turnover	1.34	0.16	0.51	1.95	4.05
Operating Profit	-2.67	-3.37	-3.90	-4.27	-5.79
Pretax Profit	-2.46	-3.31	-3.63	-3.94	-5.24
Earnings After Tax	-2.28	-2.96	-3.58	-3.83	-5.11
Profit Available For Dividend	0.00	0.00	0.00	0.00	0.00
Ordinary Dividends	0.00	0.00	0.00	0.00	0.00
Retained Profit	-2.28	0.00	0.00	0.00	0.00
Shareholders Funds	5.18	2.34	15.69	15.71	17.68
Net Current Assets	5.12	0.00	0.00	0.00	0.00
Adjusted Earnings Per Share Undiluted	0.00	-12.38	-5.89	-4.02	-4.39
Adj Earnings Per Share	0.00	-12.38	-5.89	-4.02	-4.39
Dividend Per Share	0.00	0.00	0.00	0.00	0.00

Chart

Click here for interactive charting

Company Details
Address	26th Floor, Centre Point, 103 New Oxford Street, London, WC1A 1DD
Telephone	020 7307 1620
Fax	020 7307 1680
Executives
Executive Chairman	Iain Ross (0.30% holding)
Chief Executive	as above (0.00% holding)
Finance Director	Melvyn Davies (0.10% holding)
Senior Independent Dir.	Jeremy Cook (0.10% holding)
Main Shareholders
	Insight Investments: 9.6% The Oak Fund: 9.6% Morgan Stanley Securities: 3.5% WAM Strategy Portfolio (EUR): 3.4%
Advisers
Nominated Adviser	Nomura
Nominated Broker	Nomura
Solicitors	Fasken Martineau
Auditors	Grant Thornton
Registrar	Capita Registrars

Commentary
Drug developer
Company Data
Code	SLN
Sedol	GB00084333
Shares In Issue	119.884 m
Indices
Entry on AIM	30/09/2004
Interim Results	Sep
Final Results	Mar
Year End	Dec
Accounts Due	Jun
Int div payment	n/a
Fin div payment	n/a
Int net div per share	nil
Fin net div per share	nil
Probable CGT relief	Yes